sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
ÓÕ·¢ÐÔ¶¯ÂöÖàÑùÓ²»¯¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÐÄѪ¹Üϵͳģ×Ó > ÓÕ·¢ÐÔ¶¯ÂöÖàÑùÓ²»¯¶¯ÎïÄ£×Ó

ǰÑÔ

¶¯ÂöÖàÑùÓ²»¯(atherosclerosis)ÊÇCVD×î³£¼ûºÍ×î»ù±¾µÄ²¡Àí»ù´¡¡£¶¯ÂöÖàÑùÓ²»¯µÄÖ÷Òª²¡ÀíÀú³Ì°üÀ¨Ñª¹ÜÄÚÆ¤Ï¸°ûµÄ»î»¯¡¢µ¥ºËϸ°û𤸽²¢Ç¨áãµ½ÄÚĤÏ¡¢¾ÞÊÉϸ°ûÍÌÊÉÑõ»¯ÐÞÊεÄÖ¬ÂѰ×ת»¯ÎªÅÝĭϸ°û¡¢ÄÚĤÖÐĤÔöÉú £¬×îÖÕÐγÉÖàÑù°ß¿é»òÒýÆðѪ˨¹£ÈûѪ¹Ü £¬ÒýÆðȱѪÐÔ¼²²¡¡£ºã¾ÃÒÔÀ´ £¬ һϵÁеÄʵÑ鶯Îï £¬ÈçСÊó¡¢´óÊó¡¢¼ÒÍᢵØÊ󡢺×ðÈ¡¢ÖíºÍºï×ÓµÈ £¬±»Ó¦ÓÃÓÚ¶¯ÂöÖàÑùÓ²»¯µÄÑо¿¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î¼ÒÍá¢Ð¡ÐÍÖí¡¢´óÊó¡¢Ð¡Ê󡢯äËû¶¯Îï

¡¾ÔìÄ£»úÖÆ¡¿£º

¶¯Îï»úÌåÖ¬ÖÊ´úлÔÓÂÒ £¬ÑªÖ¬Éý¸ß £¬ÈÝÒ×ÒýÆðѪ¹ÜÄÚÆ¤ËðÉË £¬µ¼ÖÂѪ¹ÜÄÚÆ¤¹¦Ð§ÔÓÂÒ¡¢Í¨Í¸ÐÔÔö¸ß £¬×îÖÕµ¼ÖÂѪ¹Ü±ÚµÄÖ¬ÖʽþÈó¡¢Ðγɶ¯ÂöÖàÑùÓ²»¯¡£Òò´Ë £¬Í¨¹ý¸øÊµÑ鶯ÎïËÇι¸ßÖ¬¡¢¸ßµ¨¹Ì´¼Òûʳ £¬·ºÆð¸ß֬Ѫ֢ £¬½ø¶øÓÕµ¼Æä×Ô¶¯Âö¼°¹Ú×´¶¯ÂöÖð½¥ÐγÉÖàÑùÓ²»¯°ß¿é¡£ÔÚ¸ßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳÖмÓÈëÉÙÁ¿µ¨ËáÑÎ £¬¿ÉÒÔÔöÌíµ¨¹Ì´¼µÄÎüÊÕ£»¼ÓÈë¼××´ÏÙÒÖÖÆÒ©ÎïÈç¼×»ùÁòÑõà×ड¢±û»ùÁòÑõà×ठ£¬¿É½øÒ»²½¼ÓËÙ¶¯Âö²¡±äµÄÐγÉ¡£

¡¾Ä£×ÓÒªÁì¡¿£º

¼ÒÍãºÑ¡ÓÃ4ÔÂÁä×óÓÒÐÛÐÔÈÕ±¾´ó¶ú°×¼ÒÍûòÐÂÎ÷À¼¼ÒÍà £¬¸øÓ躬0.3£¥µ¨¹Ì´¼Òûʳ£¨½¨ÒéÒûʳÖе¨¹Ì´¼Ë®Æ½Ð¡ÓÚ0.6£¥£© £¬¿Éʹ¼ÒÍÃѪ½¬µ¨¹Ì´¼Ñ¸ËÙÉý¸ß £¬6Öܺó¼ÒÍÃ×Ô¶¯Âö¹­¿É·ºÆðÏÔ×Ŷ¯ÂöÖàÑùÓ²»¯°ß¿é¡£Ëæ×ÅËÇιʱ¼äÑÓÉì £¬¿ÉÓÕµ¼¼ÒÍÃÐØ×Ô¶¯Âö¡¢¸¹×Ô¶¯Âö¡¢¹Ú×´¶¯Âö·ºÆðÖàÑùÓ²»¯°ß¿é¡£

СÐÍÖí£ºÑ¡ÓÃ3¡«6ÔÂÁäСÐÍÖí¡£Ö¶¯ÂöÖàÑùÓ²»¯ÒûʳÅä·½£ºµ¨¹Ì´¼1.5£¥¡«2£¥ £¬Å£ÓÍ10£¥ £¬»¨ÉúÓÍ6£¥ £¬µ¨ÑÎ0.5£¥¡«1£¥»ù´¡ÁÏ82£¥¡«83£¥¡£Í¨³£°´ÌåÖØ3£¥ËÇιСÐÍÖí¡£

´óÊ󣺺¬µ¨ËáºÍÁòëåà×वĸßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳÓÕµ¼´óÊ󱬷¢¸ß֬Ѫ֢¼°¶¯ÂöÖàÑùÓ²»¯¡£±ðµÄ £¬¸ø´óÊóËÇι¸ßµ¨¹Ì´¼Òûʳ £¬Í¬Ê±¸øÓè´ó×ÚάÉúËØD2ÄÜʹѪ½¬µ¨¹Ì´¼Ë®Æ½Éý¸ß £¬×Ô¶¯ÂöºÍ¹Ú×´¶¯Âö·ºÆðÖàÑù°ß¿é¡£

СÊó£ºÑ¡ÓÃ6~8ÖÜC57BL/6СÊó £¬Óú¬µ¨¹Ì´¼1.25£¥¡¢µ¨Ëá0.5£¥ºÍÖ¬·¾15£¥µÄÒûʳËÇι10ÖÜ £¬ÄÜÓÕµ¼³ö¶¯ÂöÖàÑùÓ²»¯ÔçÆÚ²¡±ä¡£

ÆäËû¶¯ÎѡÓÃ4~8ÖܼҼ¦ £¬¸øÓè¸ßµ¨¹Ì´¼(1£¥¡«2£¥Èë¸ßÖ¬·¾(5£¥¡«10£¥ÖíÓÍ£©Òûʳ £¬¾­ÓÉ6~10ÖÜ £¬ÐØ×Ô¶¯ÂöÖàÑù°ß¿é±¬·¢ÂÊ´ï100£¥¡£¸ë×ÓÌìÌìËÇ鵨¹Ì´¼3g/kg £¬¼Ó¼×»ùÁòÑõà×à¤0.1g £¬¿ÉÒÔ±¬·¢½ÏÁ¿ÏÔ×ŵÄÖàÑù°ß¿é¡£

¡¾Ä£×ÓÌØµã¡¿£º

 ¼ÒÍ㺸ßÖ¬ÒûʳÖе¨¹Ì´¼º¬Á¿´ï0.2£¥¡«2.0£¥ £¬¾Í¿Éʹ¼ÒÍÃѪ½¬Öе¨¹Ì´¼Å¨¶ÈѸËÙÉý¸ß £¬·ºÆð¸ßµ¨¹Ì´¼ÑªÖ¢ £¬Æô¶¯¶¯ÂöÖàÑùÓ²»¯µÄ±¬·¢Éú³¤¡£Ëæ×ÅÒûʳÖе¨¹Ì´¼º¬´ÁÔöÌí¼°Î¹ÑøÊ±¼äÑÓÉì £¬¼ÒÍö¯Âö±ÚµÄ°ß¿éÖð½¥Ôö´ó¡£¿ÉÊÇ £¬ÒûʳÖе¨¹Ì´¼º¬Á¿Ô½¸ß¶¾ÐÔÒ²Ô½´ó¡£Ò»Ñùƽ³£¶øÑÔ £¬ÓÃ0.3£¥µ¨¹Ì´¼ÒûʳËÇι¼ÒÍà £¬2Öܺó¼ÒÍÃѪ½¬µ¨¹Ì´¼Ë®Æ½¿ÉÒÔµÖ´ï400~500mg/dl £¬Ñª¹ÜÄÚÆ¤ÏÂϸ°ûÍâÖ¬ÖÊ×îÏȳÁ»ý £¬µ¥ºËϸ°ûºÍ¾ÞÊÉϸ°û½þÈó²¢·ºÆðÖ¬µÎ£»4¡«8ÖÜʱ £¬¼ÒÍÃѪ½¬µ¨¹Ì´¼Ë®Æ½ÉÏÉýµ½800~l200mg/dl £¬×Ô¶¯Âö·ºÆðÖ¬·¾ÌõÎÆ £¬ÄÚº¬ÓɾÞÊÉϸ°ûת»¯µÄÅÝĭϸ°û£»12¡«16ÖÜʱ £¬Ö¬·¾Ìõ°ßÄð³ÉÓÉϸ°ûÄÚÍâÖ¬ÖʳÁ»ýÐγɵÄÖØ´óÏËά°ß¿é £¬Æ½»¬¼¡Ï¸°ûҲת»¯ÎªÅÝĭϸ°û £¬½ºÔ­ÏËάºÏ³ÉÔöÌí £¬µ¨¹Ì´¼½á¾§ÌåÎö³ö¡£28 ÖÜÒÔºó £¬¼ÒÍÃ×Ô¶¯Âö¿ÉÖð½¥ÐγÉÖàÑù°ß¿é²¢·ºÆð¸´ºÏÐÔ²¡±ä£»¹Ú×´¶¯Âö·ºÆðÏÔ×Ų¡±ä¡£Í¼5-1/ÎÄÄ©²Êͼ5-1ʾ0.3£¥µ¨¹Ì´¼ÒûʳÓÕµ¼¼ÒÍÃ16Öܺó¶¯ÂöÖàÑùÓ²»¯²¡±äÇéÐΡ£

Öí£ºÐÄÀíÏ¢ÕùÆÊÓëÈËÀàÓÐÒ»¶¨ÏàËÆÐÔ¡£Ëæ×ÅÄê ÁäµÄÔöÌí £¬¿É×Ô¾õÇá¶È¶¯ÂöÖàÑùÓ²»¯ £¬Í¨³£ÒԸߵ¨¹Ì´¼ÒûʳÀ´¼ÓËÙ¶¯ÂöÖàÑùÓ²»¯µÄ±¬·¢¡£¸ßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳÓÕ·¢¶¯ÂöÖàÑùÓ²»¯²¡±äÖ÷Òª±¬·¢ÓÚ¸¹×Ô¶¯Âö £¬ÕâµãÓëСÊóºÍ¼ÒÍòî±ð¡£¸ßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳËÇι4~12¸öÔ £¬×Ô¶¯ÂöÖ¬·¾ÌõÎÆ²¡±äÏ£ÍûÖ÷ÒªÌåÏÖΪÄÚĤ¡Æð¸ß¶È¡¢²¡±ä¹æÄ£¡¢Ñª¹Ü±Úºñ¶ÈÖð½¥ÔöÌí¡£×Ô¶¯ÂöÏËά°ß¿é²¡±äÏ£ÍûÌåÏÖΪ°ß¿é¹æÄ£µÄÀ©´ó¡¢Â¡Æð¸ß¶ÈÔöÌí¡£Öí¶¯ÂöÖàÑùÓ²»¯Ö¬ÎÆÆÚ¶ÌÔÝ £¬ºÜ¿ìÉú³¤Îª½ÏºñµÄÏËά°ß¿é¡£8¸öÔÂ×óÓÒ·ºÆðÖ¬ÖʺË £¬12¸öÔÂ×óÓÒ·ºÆð¸Æ»¯ÔîºÍµ¨¹Ì´¼½á¾§ £¬°éÓÐÖÐĤƽ»¬¼¡±äÐÔ¡¢»µËÀºÍÔöÉúµÈ²¡±ä¡£

´óÊó£ºÑª½¬Öв»º¬µ¨¹Ì´¼´××ªÒÆÂѰ×(cholesteryl ester transfer protein,CETP) £¬Ñª½¬µ¨¹Ì´¼Ë®Æ½½ÏµÍ¡£´óÊó¶ÔÒûʳÖеĵ¨¹Ì´¼²»Ãô¸Ð¡£´¿´â¸ßµ¨¹Ì´¼Òûʳ²»Ò×Éý¸ß¾þÊóѪ½¬µ¨¹Ì´¼ £¬ºÜÄÑÓÕµ¼¶¯ÂöÖàÑùÓ²»¯¡£×ÝÈ»ºã¾Ã¸øÓè¸ßµ¨¹Ì´¼Òûʳ £¬´óÊóÒ²Ö»ÄÜÐγÉÖжȶ¯ÂöÖàÑùÓ²»¯²¡±ä £¬Õâ¾ÍÏÞÖÆÁË´óÊóÔÚ¶¯ÂöÖàÑùÓ²»¯¼²²¡Ñо¿ÖеÄÓ¦Óá£

СÊó£ºÐ¡ÊóҲȱ·¦CETP £¬ÓÉÓÚ¸ßÃܶÈÖ¬ÂѰ×(high density lipoprotein,HDL)ˮƽºÍµÍµ¨¹Ì´¼ÎüÊÕÂÊ £¬´ó´ó¶¼Ð¡ÊóƷϵ¶ÔÒûʳÖе¨¹Ì´¼²»·´Ó¦ £¬Ñª½¬µ¨¹Ì´¼²»Éý¸ß £¬¹ÊºÜÄÑÓÕµ¼³ö¶¯ÂöÖàÑùÓ²»¯°ß¿é¡£¿ÉÊÇ £¬½ü½»ÏµÐ¡Êó¶ÔÒûʳÓÕµ¼µÄ¶¯ÂöÖàÑùÓ²»¯ÔòÌåÏÖ³öÒ»¶¨Ë®Æ½µÄÃô¸ÐÐÔ¡£Óú¬µ¨¹Ì´¼1.2£¥¡¢µ¨Ëá0.5£¥ºÍÖ¬·¾15£¥µÄÒûʳËÇι10ÖÖ½ü½»ÏµÐ¡Êó £¬·¢ ÏÖËüÃǶԶ¯ÂöÖàÑùÓ²»¯Ãô¸Ðˮƽ´ÓµÍµ½¸ßÅÅÐòÈçÏ£ºBALB/cJ<C3H/J<A/J<SWR/J<NZB/J<129/J<AKR/J<DBA/2J<C57L/J<C57BL/6¡£¼òµ¥µ¨¹Ì´¼£¨º¬Á¿0.5£¥¡«1£¥£©Òûʳ²»¿ÉÓÕµ¼Ð¡Ê󱬷¢ÓÐͳ¼ÆÑ§ÒâÒåµÄѪ֬ת±ä¼°×Ô¶¯ÂöËðÉË £¬ÇÒ¼òµ¥µ¨Ëá(0.1£¥¡«0.5£¥) ÒûʳҲ²»¿ÉÓÕµ¼Ð¡ÊóѪ֬Éý¸ß¼°×Ô¶¯ÂöËðÉË¡£¿ÉÊÇ £¬º¬1.25£¥µ¨¹Ì´¼¡¢0.5£¥µ¨ËáµÄÒûʳÄÜÓÕµ¼C57BL/6СÊó·ºÆð¶¯ÂöÖàÑùÓ²»¯²¡±ä £¬ÆäÔçÆÚ°ß¿é£¨Ö¬·¾ÌõÎÆ£©ÔÚÐÎ̬ѧÉÏÓëÈËÀà°ß¿éÏàËÆ £¬µ«²¡Çé½øÒ»²½Éú³¤Ö®ºó £¬Æä²¡±ä²¿Î»ÈÔÈ»¾ÖÏÞÓÚ×Ô¶¯Âö¹­ ²¿ £¬ÇҰ߿鲻һÁ¬¡¢Ìص㲻µä·¶¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

¼ÒÍÃÌåÐÍÊÊÖÐ £¬Ö¬ÂѰ××é³ÉºÍÖ¬ÂѰ״úÐ»ÌØµãÓëÈËÏàËÆ £¬ÈçѪ½¬µÍÃܶÈÖ¬ÂѰ×(low density lipoprolein,LDL)º¬Á¿¸ß £¬¸ÎÔàÄܺϳÉApoBlOO £¬²»¿É±àÂëApoB48 mRNA £¬Ñª½¬Öи»º¬CETP £¬¸ßµ¨¹Ì´¼ÒûʳÈÝÒ×ÓÕ·¢¶¯ÂöÖàÑùÓ²»¯²¡±ä¡£ÒÔÊÇ £¬¼ÒÍÃÊÇÒûʳÓÕµ¼¶¯ÂöÖàÑùÓ²»¯×î³£¼ûµÄ¶¯ÎïÄ£×Ó¡£È»¶ø £¬¼ÒÍö¯ÂöÖàÑùÓ²»¯µÄÌØÕ÷ÓëÈËÀàÕÕ¾ÉÓÐЩ²î±ð £¬Èç·¢²¡²¿Î»ÓëÈËÀà·×ÆçÑù £¬¼ÒÍÃÒ×·¢ÓÚ×Ô¶¯Âö¹­ºÍÐØ×Ô¶¯Âö £¬¶øÈËÀàÒ×·¢ÓÚ¸¹×Ô¶¯Âö£»¼ÒÍò»Ò×±¬·¢²¢·¢Ö¢ £¬²¢ÇÒ²¡ÀíËðÉ˸ü¿¿½üÓÚ»ÆÁö²¡ £¬ÕâÓëÈËÀà·×ÆçÑù£»ÁíÍâ £¬¼ÒÍÃÊôÓÚ²ÝʳÐÔ¶¯Îï £¬¶ÔʳÎïµÄʹÓúʹúлҲÓëÈËÀà±£´æ²î±ð¡£

¹ØÓÚÄö³ÝÀදÎï¶øÑÔ £¬´ó´ó¶¼Ð¡ÊóƷϵ¶Ô¿¹¸ßµ¨¹Ì´¼ÒûʳÓÕµ¼µÄ¶¯ÂöÖàÑùÓ²»¯ £¬´óÊóµÄÖ¶¯ÂöÖàÑùÓ²»¯ÒûʳÔòÐèÌí¼ÓÌØÊâÒòËØ¡£ÆäËû¶¯ÎïËäÈ»¾ßÓÐÒ»¶¨µÄÓŵã £¬µ«ÓÉÓÚËÇÑøÖÎÀí¼°Óöȷ½ÃæµÄÔµ¹ÊÔ­ÓÉ £¬Ó¦ÓùæÄ£½ÏÕ­¡£ËäÈ»ÒûʳÓÕµ¼·¨ÓÉÓÚÆäÓÕÒòµÄ¼òµ¥ÐÔ²»¿ÉÕæÊµÄ£ÄâÈËÀදÂöÖàÑùÓ²»¯µÄ±¬·¢Éú³¤Àú³Ì £¬µ«ÓëÈËÀà·¢²¡Àú³ÌÓÐÒ»¶¨ÏàËÆÐÔ £¬¹ØÓÚÌØ¶¨Ñо¿Ä¿µÄÀ´ËµÕÕ¾ÉÓкܴóʹÓüÛÖµ¡£

 

²Î¿¼ÎÄÏ×£º

1.Áõ¶÷᪠£¬·¶½­ÁØ.ת»ùÒòÍÃÔÚ¶¯ÂöÖàÑùÓ²»¯Ñо¿ÖеÄÓ¦Óü°Ï£Íû£®Öйú¶¯ÂöÓ²»¯ÔÓÖ¾ £¬2003 £¬11(4):371-375

2.Fan J,Watanabe T.Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol Ther, 2003, 99 (3): 261-282

3.Ishibashi S,Brown MS,Goldslein JL,el al. Hyperchol eslerolemia in low density lipoprolein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clio Invest, 1993, 92(2):883-893

4.Kita T, Brown MS, Watanabe Y, el al. Deficiency of low density lipoprotein receptors in li.ver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholeslerolem.ia. Proc Natl Acad Sci USA, 1981, 78 (4):2268-2272

5.Paigen B, Morrow A, Brandon C, el al. Variation in susceptibility lo atherosclerosis among inbred strains of mice. Atherosclerosis, 1985,57 (1):65-73

6.Piedrahita JA,Zhang SH,Hagaman JR,el al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA, 1992,89 (10):4471-4475

7.Plump AS,Smith JD, Hayek T, el al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-de[icient mice created by homologous recombination in ES cells. Cell, 1992, 71 (2):343-353

8.Yu Q,Li Y,WaqarAB,et al. Temporal and quantitative analysis of atherosclerotic lesions in diet-induced hyper choleslerolemic rabbits. J Biomed Biotechnol, 2012, 2012:506159

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÐÄѪ¹Üϵͳģ×Ó > ÓÕ·¢ÐÔ¶¯ÂöÖàÑùÓ²»¯¶¯ÎïÄ£×Ó
ÓÕ·¢ÐÔ¶¯ÂöÖàÑùÓ²»¯¶¯ÎïÄ£×Ó

ǰÑÔ

¶¯ÂöÖàÑùÓ²»¯(atherosclerosis)ÊÇCVD×î³£¼ûºÍ×î»ù±¾µÄ²¡Àí»ù´¡¡£¶¯ÂöÖàÑùÓ²»¯µÄÖ÷Òª²¡ÀíÀú³Ì°üÀ¨Ñª¹ÜÄÚÆ¤Ï¸°ûµÄ»î»¯¡¢µ¥ºËϸ°û𤸽²¢Ç¨áãµ½ÄÚĤÏ¡¢¾ÞÊÉϸ°ûÍÌÊÉÑõ»¯ÐÞÊεÄÖ¬ÂѰ×ת»¯ÎªÅÝĭϸ°û¡¢ÄÚĤÖÐĤÔöÉú £¬×îÖÕÐγÉÖàÑù°ß¿é»òÒýÆðѪ˨¹£ÈûѪ¹Ü £¬ÒýÆðȱѪÐÔ¼²²¡¡£ºã¾ÃÒÔÀ´ £¬ һϵÁеÄʵÑ鶯Îï £¬ÈçСÊó¡¢´óÊó¡¢¼ÒÍᢵØÊ󡢺×ðÈ¡¢ÖíºÍºï×ÓµÈ £¬±»Ó¦ÓÃÓÚ¶¯ÂöÖàÑùÓ²»¯µÄÑо¿¡£

 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î¼ÒÍá¢Ð¡ÐÍÖí¡¢´óÊó¡¢Ð¡Ê󡢯äËû¶¯Îï

¡¾ÔìÄ£»úÖÆ¡¿£º

¶¯Îï»úÌåÖ¬ÖÊ´úлÔÓÂÒ £¬ÑªÖ¬Éý¸ß £¬ÈÝÒ×ÒýÆðѪ¹ÜÄÚÆ¤ËðÉË £¬µ¼ÖÂѪ¹ÜÄÚÆ¤¹¦Ð§ÔÓÂÒ¡¢Í¨Í¸ÐÔÔö¸ß £¬×îÖÕµ¼ÖÂѪ¹Ü±ÚµÄÖ¬ÖʽþÈó¡¢Ðγɶ¯ÂöÖàÑùÓ²»¯¡£Òò´Ë £¬Í¨¹ý¸øÊµÑ鶯ÎïËÇι¸ßÖ¬¡¢¸ßµ¨¹Ì´¼Òûʳ £¬·ºÆð¸ß֬Ѫ֢ £¬½ø¶øÓÕµ¼Æä×Ô¶¯Âö¼°¹Ú×´¶¯ÂöÖð½¥ÐγÉÖàÑùÓ²»¯°ß¿é¡£ÔÚ¸ßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳÖмÓÈëÉÙÁ¿µ¨ËáÑÎ £¬¿ÉÒÔÔöÌíµ¨¹Ì´¼µÄÎüÊÕ£»¼ÓÈë¼××´ÏÙÒÖÖÆÒ©ÎïÈç¼×»ùÁòÑõà×ड¢±û»ùÁòÑõà×ठ£¬¿É½øÒ»²½¼ÓËÙ¶¯Âö²¡±äµÄÐγÉ¡£

¡¾Ä£×ÓÒªÁì¡¿£º

¼ÒÍãºÑ¡ÓÃ4ÔÂÁä×óÓÒÐÛÐÔÈÕ±¾´ó¶ú°×¼ÒÍûòÐÂÎ÷À¼¼ÒÍà £¬¸øÓ躬0.3£¥µ¨¹Ì´¼Òûʳ£¨½¨ÒéÒûʳÖе¨¹Ì´¼Ë®Æ½Ð¡ÓÚ0.6£¥£© £¬¿Éʹ¼ÒÍÃѪ½¬µ¨¹Ì´¼Ñ¸ËÙÉý¸ß £¬6Öܺó¼ÒÍÃ×Ô¶¯Âö¹­¿É·ºÆðÏÔ×Ŷ¯ÂöÖàÑùÓ²»¯°ß¿é¡£Ëæ×ÅËÇιʱ¼äÑÓÉì £¬¿ÉÓÕµ¼¼ÒÍÃÐØ×Ô¶¯Âö¡¢¸¹×Ô¶¯Âö¡¢¹Ú×´¶¯Âö·ºÆðÖàÑùÓ²»¯°ß¿é¡£

СÐÍÖí£ºÑ¡ÓÃ3¡«6ÔÂÁäСÐÍÖí¡£Ö¶¯ÂöÖàÑùÓ²»¯ÒûʳÅä·½£ºµ¨¹Ì´¼1.5£¥¡«2£¥ £¬Å£ÓÍ10£¥ £¬»¨ÉúÓÍ6£¥ £¬µ¨ÑÎ0.5£¥¡«1£¥»ù´¡ÁÏ82£¥¡«83£¥¡£Í¨³£°´ÌåÖØ3£¥ËÇιСÐÍÖí¡£

´óÊ󣺺¬µ¨ËáºÍÁòëåà×वĸßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳÓÕµ¼´óÊ󱬷¢¸ß֬Ѫ֢¼°¶¯ÂöÖàÑùÓ²»¯¡£±ðµÄ £¬¸ø´óÊóËÇι¸ßµ¨¹Ì´¼Òûʳ £¬Í¬Ê±¸øÓè´ó×ÚάÉúËØD2ÄÜʹѪ½¬µ¨¹Ì´¼Ë®Æ½Éý¸ß £¬×Ô¶¯ÂöºÍ¹Ú×´¶¯Âö·ºÆðÖàÑù°ß¿é¡£

СÊó£ºÑ¡ÓÃ6~8ÖÜC57BL/6СÊó £¬Óú¬µ¨¹Ì´¼1.25£¥¡¢µ¨Ëá0.5£¥ºÍÖ¬·¾15£¥µÄÒûʳËÇι10ÖÜ £¬ÄÜÓÕµ¼³ö¶¯ÂöÖàÑùÓ²»¯ÔçÆÚ²¡±ä¡£

ÆäËû¶¯ÎѡÓÃ4~8ÖܼҼ¦ £¬¸øÓè¸ßµ¨¹Ì´¼(1£¥¡«2£¥Èë¸ßÖ¬·¾(5£¥¡«10£¥ÖíÓÍ£©Òûʳ £¬¾­ÓÉ6~10ÖÜ £¬ÐØ×Ô¶¯ÂöÖàÑù°ß¿é±¬·¢ÂÊ´ï100£¥¡£¸ë×ÓÌìÌìËÇ鵨¹Ì´¼3g/kg £¬¼Ó¼×»ùÁòÑõà×à¤0.1g £¬¿ÉÒÔ±¬·¢½ÏÁ¿ÏÔ×ŵÄÖàÑù°ß¿é¡£

¡¾Ä£×ÓÌØµã¡¿£º

 ¼ÒÍ㺸ßÖ¬ÒûʳÖе¨¹Ì´¼º¬Á¿´ï0.2£¥¡«2.0£¥ £¬¾Í¿Éʹ¼ÒÍÃѪ½¬Öе¨¹Ì´¼Å¨¶ÈѸËÙÉý¸ß £¬·ºÆð¸ßµ¨¹Ì´¼ÑªÖ¢ £¬Æô¶¯¶¯ÂöÖàÑùÓ²»¯µÄ±¬·¢Éú³¤¡£Ëæ×ÅÒûʳÖе¨¹Ì´¼º¬´ÁÔöÌí¼°Î¹ÑøÊ±¼äÑÓÉì £¬¼ÒÍö¯Âö±ÚµÄ°ß¿éÖð½¥Ôö´ó¡£¿ÉÊÇ £¬ÒûʳÖе¨¹Ì´¼º¬Á¿Ô½¸ß¶¾ÐÔÒ²Ô½´ó¡£Ò»Ñùƽ³£¶øÑÔ £¬ÓÃ0.3£¥µ¨¹Ì´¼ÒûʳËÇι¼ÒÍà £¬2Öܺó¼ÒÍÃѪ½¬µ¨¹Ì´¼Ë®Æ½¿ÉÒÔµÖ´ï400~500mg/dl £¬Ñª¹ÜÄÚÆ¤ÏÂϸ°ûÍâÖ¬ÖÊ×îÏȳÁ»ý £¬µ¥ºËϸ°ûºÍ¾ÞÊÉϸ°û½þÈó²¢·ºÆðÖ¬µÎ£»4¡«8ÖÜʱ £¬¼ÒÍÃѪ½¬µ¨¹Ì´¼Ë®Æ½ÉÏÉýµ½800~l200mg/dl £¬×Ô¶¯Âö·ºÆðÖ¬·¾ÌõÎÆ £¬ÄÚº¬ÓɾÞÊÉϸ°ûת»¯µÄÅÝĭϸ°û£»12¡«16ÖÜʱ £¬Ö¬·¾Ìõ°ßÄð³ÉÓÉϸ°ûÄÚÍâÖ¬ÖʳÁ»ýÐγɵÄÖØ´óÏËά°ß¿é £¬Æ½»¬¼¡Ï¸°ûҲת»¯ÎªÅÝĭϸ°û £¬½ºÔ­ÏËάºÏ³ÉÔöÌí £¬µ¨¹Ì´¼½á¾§ÌåÎö³ö¡£28 ÖÜÒÔºó £¬¼ÒÍÃ×Ô¶¯Âö¿ÉÖð½¥ÐγÉÖàÑù°ß¿é²¢·ºÆð¸´ºÏÐÔ²¡±ä£»¹Ú×´¶¯Âö·ºÆðÏÔ×Ų¡±ä¡£Í¼5-1/ÎÄÄ©²Êͼ5-1ʾ0.3£¥µ¨¹Ì´¼ÒûʳÓÕµ¼¼ÒÍÃ16Öܺó¶¯ÂöÖàÑùÓ²»¯²¡±äÇéÐΡ£

Öí£ºÐÄÀíÏ¢ÕùÆÊÓëÈËÀàÓÐÒ»¶¨ÏàËÆÐÔ¡£Ëæ×ÅÄê ÁäµÄÔöÌí £¬¿É×Ô¾õÇá¶È¶¯ÂöÖàÑùÓ²»¯ £¬Í¨³£ÒԸߵ¨¹Ì´¼ÒûʳÀ´¼ÓËÙ¶¯ÂöÖàÑùÓ²»¯µÄ±¬·¢¡£¸ßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳÓÕ·¢¶¯ÂöÖàÑùÓ²»¯²¡±äÖ÷Òª±¬·¢ÓÚ¸¹×Ô¶¯Âö £¬ÕâµãÓëСÊóºÍ¼ÒÍòî±ð¡£¸ßÖ¬¡¢¸ßµ¨¹Ì´¼ÒûʳËÇι4~12¸öÔ £¬×Ô¶¯ÂöÖ¬·¾ÌõÎÆ²¡±äÏ£ÍûÖ÷ÒªÌåÏÖΪÄÚĤ¡Æð¸ß¶È¡¢²¡±ä¹æÄ£¡¢Ñª¹Ü±Úºñ¶ÈÖð½¥ÔöÌí¡£×Ô¶¯ÂöÏËά°ß¿é²¡±äÏ£ÍûÌåÏÖΪ°ß¿é¹æÄ£µÄÀ©´ó¡¢Â¡Æð¸ß¶ÈÔöÌí¡£Öí¶¯ÂöÖàÑùÓ²»¯Ö¬ÎÆÆÚ¶ÌÔÝ £¬ºÜ¿ìÉú³¤Îª½ÏºñµÄÏËά°ß¿é¡£8¸öÔÂ×óÓÒ·ºÆðÖ¬ÖʺË £¬12¸öÔÂ×óÓÒ·ºÆð¸Æ»¯ÔîºÍµ¨¹Ì´¼½á¾§ £¬°éÓÐÖÐĤƽ»¬¼¡±äÐÔ¡¢»µËÀºÍÔöÉúµÈ²¡±ä¡£

´óÊó£ºÑª½¬Öв»º¬µ¨¹Ì´¼´××ªÒÆÂѰ×(cholesteryl ester transfer protein,CETP) £¬Ñª½¬µ¨¹Ì´¼Ë®Æ½½ÏµÍ¡£´óÊó¶ÔÒûʳÖеĵ¨¹Ì´¼²»Ãô¸Ð¡£´¿´â¸ßµ¨¹Ì´¼Òûʳ²»Ò×Éý¸ß¾þÊóѪ½¬µ¨¹Ì´¼ £¬ºÜÄÑÓÕµ¼¶¯ÂöÖàÑùÓ²»¯¡£×ÝÈ»ºã¾Ã¸øÓè¸ßµ¨¹Ì´¼Òûʳ £¬´óÊóÒ²Ö»ÄÜÐγÉÖжȶ¯ÂöÖàÑùÓ²»¯²¡±ä £¬Õâ¾ÍÏÞÖÆÁË´óÊóÔÚ¶¯ÂöÖàÑùÓ²»¯¼²²¡Ñо¿ÖеÄÓ¦Óá£

СÊó£ºÐ¡ÊóҲȱ·¦CETP £¬ÓÉÓÚ¸ßÃܶÈÖ¬ÂѰ×(high density lipoprotein,HDL)ˮƽºÍµÍµ¨¹Ì´¼ÎüÊÕÂÊ £¬´ó´ó¶¼Ð¡ÊóƷϵ¶ÔÒûʳÖе¨¹Ì´¼²»·´Ó¦ £¬Ñª½¬µ¨¹Ì´¼²»Éý¸ß £¬¹ÊºÜÄÑÓÕµ¼³ö¶¯ÂöÖàÑùÓ²»¯°ß¿é¡£¿ÉÊÇ £¬½ü½»ÏµÐ¡Êó¶ÔÒûʳÓÕµ¼µÄ¶¯ÂöÖàÑùÓ²»¯ÔòÌåÏÖ³öÒ»¶¨Ë®Æ½µÄÃô¸ÐÐÔ¡£Óú¬µ¨¹Ì´¼1.2£¥¡¢µ¨Ëá0.5£¥ºÍÖ¬·¾15£¥µÄÒûʳËÇι10ÖÖ½ü½»ÏµÐ¡Êó £¬·¢ ÏÖËüÃǶԶ¯ÂöÖàÑùÓ²»¯Ãô¸Ðˮƽ´ÓµÍµ½¸ßÅÅÐòÈçÏ£ºBALB/cJ<C3H/J<A/J<SWR/J<NZB/J<129/J<AKR/J<DBA/2J<C57L/J<C57BL/6¡£¼òµ¥µ¨¹Ì´¼£¨º¬Á¿0.5£¥¡«1£¥£©Òûʳ²»¿ÉÓÕµ¼Ð¡Ê󱬷¢ÓÐͳ¼ÆÑ§ÒâÒåµÄѪ֬ת±ä¼°×Ô¶¯ÂöËðÉË £¬ÇÒ¼òµ¥µ¨Ëá(0.1£¥¡«0.5£¥) ÒûʳҲ²»¿ÉÓÕµ¼Ð¡ÊóѪ֬Éý¸ß¼°×Ô¶¯ÂöËðÉË¡£¿ÉÊÇ £¬º¬1.25£¥µ¨¹Ì´¼¡¢0.5£¥µ¨ËáµÄÒûʳÄÜÓÕµ¼C57BL/6СÊó·ºÆð¶¯ÂöÖàÑùÓ²»¯²¡±ä £¬ÆäÔçÆÚ°ß¿é£¨Ö¬·¾ÌõÎÆ£©ÔÚÐÎ̬ѧÉÏÓëÈËÀà°ß¿éÏàËÆ £¬µ«²¡Çé½øÒ»²½Éú³¤Ö®ºó £¬Æä²¡±ä²¿Î»ÈÔÈ»¾ÖÏÞÓÚ×Ô¶¯Âö¹­ ²¿ £¬ÇҰ߿鲻һÁ¬¡¢Ìص㲻µä·¶¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

¼ÒÍÃÌåÐÍÊÊÖÐ £¬Ö¬ÂѰ××é³ÉºÍÖ¬ÂѰ״úÐ»ÌØµãÓëÈËÏàËÆ £¬ÈçѪ½¬µÍÃܶÈÖ¬ÂѰ×(low density lipoprolein,LDL)º¬Á¿¸ß £¬¸ÎÔàÄܺϳÉApoBlOO £¬²»¿É±àÂëApoB48 mRNA £¬Ñª½¬Öи»º¬CETP £¬¸ßµ¨¹Ì´¼ÒûʳÈÝÒ×ÓÕ·¢¶¯ÂöÖàÑùÓ²»¯²¡±ä¡£ÒÔÊÇ £¬¼ÒÍÃÊÇÒûʳÓÕµ¼¶¯ÂöÖàÑùÓ²»¯×î³£¼ûµÄ¶¯ÎïÄ£×Ó¡£È»¶ø £¬¼ÒÍö¯ÂöÖàÑùÓ²»¯µÄÌØÕ÷ÓëÈËÀàÕÕ¾ÉÓÐЩ²î±ð £¬Èç·¢²¡²¿Î»ÓëÈËÀà·×ÆçÑù £¬¼ÒÍÃÒ×·¢ÓÚ×Ô¶¯Âö¹­ºÍÐØ×Ô¶¯Âö £¬¶øÈËÀàÒ×·¢ÓÚ¸¹×Ô¶¯Âö£»¼ÒÍò»Ò×±¬·¢²¢·¢Ö¢ £¬²¢ÇÒ²¡ÀíËðÉ˸ü¿¿½üÓÚ»ÆÁö²¡ £¬ÕâÓëÈËÀà·×ÆçÑù£»ÁíÍâ £¬¼ÒÍÃÊôÓÚ²ÝʳÐÔ¶¯Îï £¬¶ÔʳÎïµÄʹÓúʹúлҲÓëÈËÀà±£´æ²î±ð¡£

¹ØÓÚÄö³ÝÀදÎï¶øÑÔ £¬´ó´ó¶¼Ð¡ÊóƷϵ¶Ô¿¹¸ßµ¨¹Ì´¼ÒûʳÓÕµ¼µÄ¶¯ÂöÖàÑùÓ²»¯ £¬´óÊóµÄÖ¶¯ÂöÖàÑùÓ²»¯ÒûʳÔòÐèÌí¼ÓÌØÊâÒòËØ¡£ÆäËû¶¯ÎïËäÈ»¾ßÓÐÒ»¶¨µÄÓŵã £¬µ«ÓÉÓÚËÇÑøÖÎÀí¼°Óöȷ½ÃæµÄÔµ¹ÊÔ­ÓÉ £¬Ó¦ÓùæÄ£½ÏÕ­¡£ËäÈ»ÒûʳÓÕµ¼·¨ÓÉÓÚÆäÓÕÒòµÄ¼òµ¥ÐÔ²»¿ÉÕæÊµÄ£ÄâÈËÀදÂöÖàÑùÓ²»¯µÄ±¬·¢Éú³¤Àú³Ì £¬µ«ÓëÈËÀà·¢²¡Àú³ÌÓÐÒ»¶¨ÏàËÆÐÔ £¬¹ØÓÚÌØ¶¨Ñо¿Ä¿µÄÀ´ËµÕÕ¾ÉÓкܴóʹÓüÛÖµ¡£

 

²Î¿¼ÎÄÏ×£º

1.Áõ¶÷᪠£¬·¶½­ÁØ.ת»ùÒòÍÃÔÚ¶¯ÂöÖàÑùÓ²»¯Ñо¿ÖеÄÓ¦Óü°Ï£Íû£®Öйú¶¯ÂöÓ²»¯ÔÓÖ¾ £¬2003 £¬11(4):371-375

2.Fan J,Watanabe T.Transgenic rabbits as therapeutic protein bioreactors and human disease models. Pharmacol Ther, 2003, 99 (3): 261-282

3.Ishibashi S,Brown MS,Goldslein JL,el al. Hyperchol eslerolemia in low density lipoprolein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clio Invest, 1993, 92(2):883-893

4.Kita T, Brown MS, Watanabe Y, el al. Deficiency of low density lipoprotein receptors in li.ver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholeslerolem.ia. Proc Natl Acad Sci USA, 1981, 78 (4):2268-2272

5.Paigen B, Morrow A, Brandon C, el al. Variation in susceptibility lo atherosclerosis among inbred strains of mice. Atherosclerosis, 1985,57 (1):65-73

6.Piedrahita JA,Zhang SH,Hagaman JR,el al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA, 1992,89 (10):4471-4475

7.Plump AS,Smith JD, Hayek T, el al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-de[icient mice created by homologous recombination in ES cells. Cell, 1992, 71 (2):343-353

8.Yu Q,Li Y,WaqarAB,et al. Temporal and quantitative analysis of atherosclerotic lesions in diet-induced hyper choleslerolemic rabbits. J Biomed Biotechnol, 2012, 2012:506159

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿